Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sent a message with a question through Social Media... FaceBook.... No reply
Still surprises me with all the upside potential that this stock is trading as low as it is... It is only a short matter of time before this company takes off big...
Thanks... Good to know... I actually bought in more on this last dip. I can’t see how investors aren’t jumping in on this now with up coming approvals. Company updates would help uncertain investors...
Rob Bowdring says everything is OK. Proceeding according to plan outlined in 10Q. Looking for financing while doing training sessions. Working on potential partnerships. Cannot give info until complete.
So what the heck is going on now? Crash and Burn?
OK.... so why the heck is this stock dropping like a rock... any good reason? did 4th Qtr Sales do any good?
I sent Katie a request for an update. They usually respond promptly.
Happy New Year! (I hope)
Clinics:
- I want information on clinics. How many are active (accepting clients) vs soon to be active (in training... Etc)
- breakdown of all clinics and number of units bought
- clinic birth rates
- more details on Calgary clinic delays. Canada is going to be huge and we all expected interest/waitlists they reported to show up in revenues last few quarters
- maybe asking to much but help us understand agreements with new clinics. Do they get any freebies or discounts at first, how much do they pay per treatment (price previously communicated or have they lowered price), required order quantity when they sign up (hopefully not wasting time training clinics that are not serious)
** Main point in terms of clinics is what we know (website clinic list and Calgary news) does not match up to revenues being reported, why?
Financing:
- what are their plans? Still looking?
- plans to improve shareholder equity? Large amount of salaries deferred for years is killing this stock
- any dillution? Has mgmt sold shares? Any insight into Dr. R selling
small number of shares?
** They have to convince shareholders they have a plan! I know they have come way too far for bankruptcy but I constantly hear it from shareholders.
Marketing/increasing exposure:
- any luck with insurance coverage conversations?
- why hardly any social media presence?
- Oprah/Ellen type shows?
** Main point is they have done a horrible job spreading the news. In this day and age, there are ways to do it effectively and cheap.
Management:
- What has Katie been up to? It has been so long since we heard from her. Is she committed to this company or other job?
- what have new board members done? New ideas...etc?
- when do they plan on starting quarterly report calls? Act like a viable company and at least communicate quarterly reporting dates in advance.
** Trust in current mgmt is at an all time low.
.... To be continued
Any and all information on this company is greatly appreciated... I am decently invested here... Looks like a great product and nice company with very strong upside potential... just very little info out there, trading volume is low and this thread is stagnant... This company does very little to inform their investors... Can you elaborate what we are waiting on Katie to speak to besides results... Details and info please... Thanks in Advance
Waiting on an update from Katie!
Just a test to make sure this board is still working! Where is everyone at?
After November 3rd approval.... What will 4th QTR Sales come in at?
I believe this will Be Big in the near future...
http://www.nasdaq.com/press-release/invo-bioscience-reports-third-quarter-2017-financial-results--20171114-00687
This truly seems to be a great upcoming company. Any idea why it has such low volume and hasn’t picked up a lot of steam... is this a sleeper?
Timing is good for a Buy in on this company... Sales will follow... This is the time to get in at a great price. The word will be getting out with better and better results... Hang on...
Common Q3 PR!! Will this be the quarter we see all the good news (clinics, # of treatments, waitlists..) make a difference?
$IVOB First INVO Babies Born in California
https://www.otcmarkets.com/stock/IVOB/news
GREENBRAE, CA, MEDFORD, MA / ACCESSWIRE / September 25, 2017 / Dr. Peter Uzelac, a Reproductive Endocrinologist with the Marin Fertility Center in Greenbrae, CA, and INVO Bioscience, Inc. (OTC: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, announced today that the first babies to be successfully conceived in California using the INVOcell technology were born in August in San Francisco.
Marin Fertility Center has been offering the INVOcell and INVO procedure since late 2016, when the twins were conceived. Dr. Uzelac said, "This technology simplifies the IVF process, driving down the cost to make it more accessible to patients that would not otherwise be able to afford care."
The mother of the twins, a 30-year-old woman, had tubal factor infertility and had been trying for two years to conceive. Dr. Jennifer Agard, a reproductive endocrinologist with Marin Fertility Center since 2015, was the lead doctor treating the patient looking for a more cost-effective alternative to traditional IVF.
"INVO Bioscience is delighted to have Marin Fertility Center furthering our mission in California to provide affordable, safe and effective treatment for infertility," said Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience. "Drs. Uzelac and Agard, along with the team at Marin Fertility Center, were early adopters of the INVOcell Intravaginal Culture System, and we share in the joy of family building for these deserving patients."
Dr. Uzelac continued, "We are thrilled to be part of this family's story and excited that we can offer our patients a more cost-efficient solution to infertility treatment. INVOcell is an excellent choice for those patients who desire a less invasive experience during their fertility treatment."
The INVOcell is a small capsule that is used in infertility treatment for the incubation of eggs, sperm and embryo development. Unlike conventional infertility treatments such as in vitro fertilization (IVF), where the eggs and sperm develop into embryos in a laboratory, the INVOcell utilizes the woman's vagina as a natural incubator to support embryo development. INVOcell technology offers patients a more personal approach to achieving pregnancy, decreasing the risk of multiple births and reduces the chance for creating unused embryos.
About Marin Fertility Center:
Marin Fertility Center is Northern California's premiere fertility program, offering personalized care using a number of novel treatment approaches, including INVOcell, IVM and Moderate IVF. Marin Fertility Center uses new technology to reimagine the patient experience, reducing the amount of medication and the number of office visits required, resulting in less prohibitive costs. The clinic is led by Dr. Peter Uzelac, a Board-Certified expert in Reproductive Endocrinology and Infertility.
For more information about INVOcell treatment at Marin Fertility Center visit: www.marinfertility.com or contact Jamie Vigil, 415-925-9409,
jvigil@marinfertility.com.
About INVO Bioscience:
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com/.
Safe Harbor Statement:
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Kathleen Karloff, CEO
INVO Bioscience, Inc.
978-878-9505 ext. 504
kkarloff@invobio.com
SOURCE: INVO Bioscience, Inc.
Can someone tell me what went on with this stock late in the day.... I can find no info...
getting down there now. twenty cents.starting watch closely .
Huge volume today! Thoughts on what is causing it?
Dr. Francisco Arredondo Opens First U.S. INVOcell Center in McAllen, Texas
ACCESSWIRE ACCESSWIRESeptember 6, 2017Comment
MCALLEN, TX and MEDFORD, MA / ACCESSWIRE / September 6, 2017 / INVO Bioscience, Inc. (OTC PINK: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced the opening of the United States' first fertility center to exclusively offer the INVOcell device and solution to patients. The INVOcell center is an extension of RMA of Texas, a leading provider of fertility-based solutions with multiple locations in Texas. The INVOcell center, based in McAllen, Texas, is under the direction of Dr. Francisco Arredondo, MD, a respected and experienced board certified reproductive endocrinologist who has published numerous papers on infertility.
Dr. Francisco Arredondo opens first U.S. INVOcell Center in McAllen, Texas
Branded by Dr. Arredondo as Smart IVF, the center will offer INVOcell's patented medical device that enables egg fertilization and early embryo development to take place in the woman's body, in vivo. By utilizing the women's own body as an incubator, it decreases the number of office visits, blood work, monitoring and other costs associated with traditional in vitro fertilization (IVF). These decreased input costs translate into an approximate 50% reduction in the overall cost per cycle for patients. Despite the decreased costs, pregnancy rates with INVOcell are equivalent to that of traditional IVF.
Francisco Arredondo, MD MPH, founder of Smart IVF, a subsidiary of RMA of Texas, commented, "INVOcell is a true breakthrough for infertility treatment. I began offering the INVOcell solution to patients at my fertility clinics in San Antonio and Austin in April 2016. Due to the success we had in expanding the accessibility of infertility treatment to patients, we decided to open a center where we would exclusively offer the INVOcell solution. Since our pre-launch in April 2017, we have now treated 68 patients in our new McAllen location. I am excited about the opportunity afforded to us by INVOcell to bring an effective and affordable fertility treatment option to Southern Texas."
"Dr. Arredondo has been an early champion of the INVOcell solution," said Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience. "The successful launch of a clinic exclusively offering INVOcell in McAllen, Texas, a location void of traditional IVF centers, validates a number of assumptions we have about the opportunity to expand accessibility to fertility treatment. We look forward to working with Dr. Arredondo and other physicians around the United States to bring INVOcell centers to large metropolitan areas, as well as smaller remote locations, where traditional IVF centers would be financially unfeasible."
INVOcell coming to the UK
Tiny incubator the size of champagne cork may transform IVF treatment and cut costs by nurturing developing embryos inside a woman's body
The INVOcell mini-incubator is as effective as conventional IVF and can make fertility treatment cheaper and faster due to fewer drugs and less monitoring
The manufacturer says it could be approved in UK private clinics next year
INVOcell costs about £5,000 per cycle, so the main advantage is a lower cost
By JO WILLEY FOR THE DAILY MAIL
PUBLISHED: 20:31 EDT, 21 August 2017 | UPDATED: 21:07 EDT, 21 August 2017
A tiny incubator which nurtures developing embryos inside a woman’s body may prove an alternative to traditional IVF.
The INVOcell mini-incubator, which is the size of a champagne cork, is as effective as conventional IVF and can make fertility treatment cheaper and faster because fewer drugs and less monitoring are needed.
It could be approved for use in UK private clinics as early as next year, according to the manufacturer — and by the NHS soon after, potentially giving thousands more women the chance to become mothers.
A tiny incubator which nurtures developing embryos inside a woman¿s body may prove an alternative to traditional IVF (stock photo of IVF) +2
A tiny incubator which nurtures developing embryos inside a woman’s body may prove an alternative to traditional IVF (stock photo of IVF)
The clear plastic chamber with developing embryos in it, is placed inside the woman’s body. This more closely replicates the conditions of natural conception in the womb, maximising the chance of a successful embryo that will implant and develop into a healthy baby.
In a study published in the Journal of Reproduction and Genetics, women who had the INVOcell treatment were just as likely to give birth as those who underwent traditional IVF, where an egg is fertilised in a test tube or dish and the embryo placed briefly in a laboratory incubator to grow.
RELATED ARTICLES
Previous
1
Next
Less than HALF of US parents are following doctor's advice...
Will my cooker stop a pacemaker working? MARTIN SCURR...
ME AND MY OPERATION: Back implant that banishes pain AND...
High-tech mat that detects foot ulcers BEFORE they develop:...
SHARE THIS ARTICLE
Share
40 shares
About 50,000 women have IVF each year in Britain. But it is being increasingly rationed across the NHS, despite official guidance from NICE recommending that all under-40s should be entitled to three cycles of IVF if they need it.
However, this is not mandatory and just 12 per cent of clinical commissioning groups in England offer three cycles.
In a study published in the Journal of Reproduction and Genetics, women who had the INVOcell treatment were just as likely to give birth as those who underwent traditional IVF +2
In a study published in the Journal of Reproduction and Genetics, women who had the INVOcell treatment were just as likely to give birth as those who underwent traditional IVF
Private clinics charge up to £15,000 a cycle — and it takes an average of three treatment cycles for a successful pregnancy.
INVOcell costs about £5,000 per cycle, so the main advantage is a lower cost for the same chance of pregnancy. The process is also shorter than traditional IVF, as less medication is given to a woman to prepare her body for the pregnancy.
With conventional IVF, she first undergoes a month of daily injections of high-dose drugs to jump-start her ovaries to produce more eggs that can be extracted for fertilisation. On average, 15 eggs are collected and mixed with sperm for fertilisation.
With INVOcell, researchers say they need to extract only six to eight eggs, so women can have lower doses of the drugs and the process is shorter, completed in about three clinic visits compared with ten for conventional IVF.
With IVF, once extracted, the eggs are injected with sperm in a laboratory and left for 18 hours to be fertilised.
They are then checked by a specialist and the embryos deemed successful are transferred to a special incubator that mimics the conditions of the fallopian tube, where fertilisation normally takes place inside the woman’s reproductive tract.
This requires careful monitoring to ensure the balance of gases is correct and the desired temperature, pH level and nutrients are maintained for embryo growth. Successful embryos will then go through a further stage of development in the laboratory as they form more cells and specialised structures, until they reach what is known as the blastocyst stage.
After two days they are checked again and the healthiest ones are implanted into a woman’s uterus.
With the new technique, healthy eggs are placed with sperm inside the INVOcell device — to get the best fertilisation rate, doctors mix one egg with 30,000 sperm cells.
The device is then put back into the woman’s vagina and into the cervix, much like a tampon, for fertilisation to occur in her body. There, the manufacturer says the temperature, pH balance and mix of carbon dioxide and oxygen replicate the usual environment for conception, so there is no need for checks to regulate these.
The developing embryos don’t undergo the checks done in traditional IVF, though, so there is a theoretical risk that abnormal embryos won’t be detected early and won’t implant successfully.
After three to five days, the INVOcell incubator is removed by a doctor and the best embryos — those that have reached blastocyst stage — are transferred to the womb, as with traditional IVF.
Recently, a trial at the Centre for Associated Reproduction, in Texas, found that women who had the INVOcell treatment were just as likely as those undergoing traditional IVF to have a successful pregnancy and a live baby.
Of the 20 women undergoing IVF, 12 got pregnant and delivered 15 babies, including three sets of twins. In the INVOcell group, 11 of 20 women gave birth to 16 babies, including five sets of twins.
Professor Geeta Nargund, medical director at Create Fertility, says: ‘I would support any easier method, new technology or device that would help to reduce the cost of IVF and increase accessibility, as long as they meet our regulatory standards.’
However, she cautioned that abnormal embryos may not always be detected with INVOcell.
The company is awaiting review for the device to be approved for sale in the UK. This is expected early next year.
I am impressed! 10x improvement in regards to their net loss. Maybe next quarter they will be profitable since will include the highly successful Calgary clinic!
INVO Bioscience Reports Record Second Quarter 2017 Financial Results
https://finance.yahoo.com/news/invo-bioscience-reports-record-second-200500402.html
1st Houston clinic! Also, finally a good article getting some press. Check yahoo
Great interview with Katie:
Amazing news today https://www.otcmarkets.com/news/otc-market-headline?id=826490
Ranoux Claude has filed a new activist 13D, reporting 19.0% ownership in $IVOB - https://fintel.io/soh/us/ivob/ranoux-claude and https://fintel.io/i/ranoux-claude
INVO Bioscience (IVOB): Disrupting the Infertility Market
Equities Research Follow | Tuesday, 13 June 2017 14:53 (EST)
According to the Centers for Disease Control, about 12% of women in the US between the ages of 15 and 44 have difficulty conceiving. That's about 7.4 million women, based on 2010 census numbers, and worldwide estimates place the number of infertile women at 150 million. Approximately $3 billion is spent annually in the US on in-vitro fertilization (IVF) and intrauterine insemination (IUI) cycles, and Allied Market Research projects the global IVF market alone to exceed $21 billion by 2020.
The vast majority - 98% - of infertile patients go untreated, with cost and proximity to treatment centers as the greatest hindrance. We've been following a company called INVO Bioscience (OTC: IVOB) that has developed the first new device and treatment for infertility in more than 30 years that produces results comparable to IVF at half the cost.
INVOcell device
The company's INVOcell device was approved by the FDA in 2015 as a De Novo Class II device, enabling egg fertilization and early embryo development in the woman’s body. The device achieves pregnancy rates comparable to IVF while saving about $8,000 per pregnancy. The company has now signed up 50 clinics in 11 states to begin offering or referring the INVOcell device and procedure.
Source: INVO Bioscience Corporate Presentation, June 2017
INVOcell enables fertilization to occur within the women’s own body (in vivo), a powerful motivator for many patients and the only acceptable option available to some patients for religious and cultural reasons. Results have been comparable with IVF but requiring fewer visits to the fertility specialist saving time and expense for patients. The device will enable broader access to IVF treatment from a geographical perspective as currently the approximately 500 IVF centers in US are exclusively located in large urban centers. With a requirement for significantly less capital equipment costs and leasehold space to start an INVOcell equipped center, more cities and areas with lower population can support a fertility center.
OTC Pink - But Now Fully Reporting and Caught Up with the SEC
The company's stock trades on the Pink Open Market segment of the OTC market, but with its Super 10-K filing in March 2017 and subsequent regular 10-K and 10-Q filings in April and May, respectively, INVO Bioscience is now fully caught up with the SEC. CEO Katie Karloff, in the company's Q1 press release, stated the company has "made great progress in attracting physicians to offer the INVOcell device and procedure, with 27 new clinics coming on board since the beginning of the year. We anticipate that as physician training occurs in the coming months, we will see increased utilization with successful pregnancy rates which will continue to drive further adoption in the future. Importantly, we are seeing the adoption of clinics exclusively providing the INVOcell treatment, creating a model that we believe will ultimately become the key driver of growth for the Company – INVO Clinics owned by INVO Bioscience."
Issues to Consider
There are the usual liquidity risks associated with thinly traded OTC stocks, and the company does have balance sheet concerns of which investors should be aware. As of March 31st, there was less than $40,000 in cash, $675,000 in accounts payable (which the company says is all being managed pending increased revenue) and $3.6 million in back salary, expenses and notes owed to members of management and board.
INVO Bioscience has a commercially viable product that is addressing a very large market opportunity, and we're encouraged by the company's success in getting the INVOcell device adopted by treatment clinics and its attention to getting current with regulatory filings. We'll be following this company to see if it can continue to gain traction by clinics and physicians, and shore up its balance sheet in the process.
https://www.equities.com/news/invo-bioscience-ivob-disrupting-the-infertility-market
“I see INVO as the paradigm shift in reproductive medicine and the solution to improving access to treatment,” commented Dr. Perez.
http://eprnews.com/procreate-fertility-center-announces-first-clinical-pregnancy-in-virginia-using-the-invo-procedure-140767/
More good press:
http://fox2now.com/2017/05/29/a-new-approach-to-fertility-treatment/
It's best for the LT those types stear clear. I quite happy ihubbers aren't flocking to this.
Hard to believe that people chase worthless penny stocks in favor of this gem!
10-Q out! Looking good.
http://www.otcmarkets dot com/stock/IVOB/filings
send me a message when she starts up.i always loved this stock
Calgary Clinic started treating patients now. Lets get this party started!!
http://www.marketwired.com/press-release/effortless-ivf-canada-begins-treating-patients-countrys-first-low-cost-fertility-clinic-2213115.htm
Yes, sort of, but not technically. We are waiting on the 10qs for 2016.
Soon after that the 2017 1st quarter 10q.
some filings out for april.they must be current?
IVOB is one to watch.been awhile since i played this one.
INVO with the fake out! Releases 2016 10-K ahead of (revised) schedule!
OTC goes from PINK NO INFO to PINK CURRENT INFO!
This may not stick as they still need to file 2016 10-Qs but that is weeks away.
Crazy to finally see Current associated with IVOB!!
It has been a looooooooong road.
http://www.otcmarkets.com/stock/IVOB/filings
Love this, they are ready to roll.......
To date, we have achieved a series of important steps in the development and manufacturing of the INVOcell, including:
·Manufacturing: Our parts and manufacturing processes have been validated. Our facilities and Quality Management Systems (QMS) have been inspected twice by the FDA and have received very good reports. Manufacturing of inventory is ongoing. As of January 31, 2017, we had approximately 2,400 INVOcell devices ready for sale, and an additional approximately 5,000 devices molded and ready for assembly, sterilization and packaging. Our suppliers provide us with virtually an unlimited capability, with all manufacturing done in New England.
Ok my fellow poster friend here on IVOB Shorthound. We are a community here so let's see what Doody can do for us - GLTU
HCIT
My apologies, I thought you were referring to the winfertility news.
Followers
|
37
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1116
|
Created
|
04/05/09
|
Type
|
Free
|
Moderators |
INVO Bioscience Product InformationINVO Bioscience's INVOcell will revolutionize the treatment of infertility. The INVOcell, pictured below, replaces the IVF laboratory and allows conception to take place naturally inside the woman's body. INVO Bioscience's INVOcell device and the INVO process will be much less expensive than traditional IVF and is comparable in pregnancy rate. Also, the INVO procedure is simple so it will be available in physician's offices. The INVOcell Device The INVOcell device and procedure were developed by Dr. Claude Ranoux. Over 800 clinical cases using prototype devices have been published in the medical literature. The INVOcell is a precisely designed and manufactured device. The INVOcell is manufactured in the U.S. by a company that is ISO-13485 certified. INVO Bioscience has 5 current patents on the INVOcell device and procedure.“This technology represents an exciting and important new treatment option for infertility.” Dr. Leo Bonaventura, INVOcell Clinical Investigator and member of INVO Bioscience's Board of Advisors, |
Chat forum for woman who were in the Trials! Lots of great feedback! |
11/03/2015 - Pr Newswire | |
The Economist-Oct 25, 2014 IT IS not quite do-it-yourself IVF, but it is close. An INVOcell, brainchild of Claude Ranoux of INVO Bioscience, in Medford, Massachusetts, is a device that allows ... | |
The 'champagne cork' mini incubator that could halve cost of IVFDaily Mail-Oct 22, 2014 In a pilot study, women treated using the INVOcell device were just as likely to ... INVO Bioscience hopes to have the device on sale in the US by the end of this ... | |
Mini 'body incubator' may halve cost of IVFIndependent Online-Nov 4, 2014 In a pilot study of 33 infertile women, those treated using the INVOcell ... INVO Bioscience hopes to have the device on sale in the US by the end of this year. | |
The INVO procedure has been published in The Scientific World Journal! INVO Procedure: Minimally Invasive IVF as an Alternative Treatment Option for Infertile Couples Click Here for Active Stock Bid Information IR@INVOBio.com |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |